Pfizer Shares Decline Following Mixed Results for Monthly Obesity Drug Candidate
Pfizer reported sustained weight loss for its obesity drug PF-3944 but noted a 10 percent patient discontinuation rate, driving a decline in company shares.
Insights:
Pfizer Inc. released mid-stage trial data for its monthly obesity treatment PF-3944 today, February 4, 2026, showing sustained weight loss in patients at 28 weeks. However, the report also revealed that approximately 10% of participants discontinued the trial due to adverse side effects. The disclosure of these results coincided with the release of the company's fourth-quarter earnings and triggered a more than 3% decline in the shares of Pfizer Inc. within the US 
US market.
US market.
